Pharmaceutical

AD/PD 2024: exploring cutting-edge therapies for ALS

While some biotechs are attempting to develop disease-modifying therapies for amyotrophic lateral sclerosis (ALS), it has proven challenging.

Mar 9, 2024 - 18:00
AD/PD 2024: exploring cutting-edge therapies for ALS
While some biotechs are attempting to develop disease-modifying therapies for amyotrophic lateral sclerosis (ALS), it has proven challenging.
Read the original article

Tags:

Previous Article

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

Next Article

FDA delays action on Lilly’s donanemab, intent on advisory committee meeting

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain

STAT+: Moonlake’s less-than-transparent data disclosure...

Jun 28, 2023

Super DC Vaccine by Shanghai Cell Therapy Group for Sol...

Oct 3, 2023

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

Ligand Pharmaceuticals to acquire APEIRON Biologics for...

Jul 10, 2024